How semaglutide is measured in plasma

A validated method for measuring semaglutide in human plasma has been reported in Bioanalysis (August 2026). The paper from Tudan and colleagues describes a triple-quadrupole HPLC-MS/MS assay that quantifies semaglutide across a range of 5 to 200 ng/mL in plasma, with accuracy between 92.7% and 109.4% and precision below 10.6%^[1]. Those numbers may seem like technical fine print, but they matter for anyone tracking pharmacokinetic research, evaluating compounded products, or following how analytical science keeps pace with one of the most widely prescribed peptide drugs on the market.

What the method does

HPLC-MS/MS stands for high-performance liquid chromatography coupled with tandem mass spectrometry. The technique separates compounds in a biological sample by their chemical properties, then uses two stages of mass filtering to identify and quantify the target molecule with high specificity. For a peptide as large and structurally complex as semaglutide, this two-stage confirmation matters: you want to be sure you are measuring semaglutide and not a structurally related degradant or co-eluting compound^[1].

The Tudan et al. method uses protein precipitation with a stable isotope-labeled internal standard to prepare plasma samples. The internal standard is a chemically identical version of the target, distinguished only by the incorporation of heavy isotopes (typically deuterium or carbon-13). Because it behaves identically to the analyte through every step of preparation and measurement, it corrects for any variability introduced by the sample-handling process. The result is high analyte recovery with minimal matrix effects^[1].

Why validation matters

Publishing a method is not the same as validating it. The 2022 FDA M10 guidance on bioanalytical method validation sets out the criteria an assay must meet before its data can support regulatory submissions, pharmacokinetic studies, or clinical monitoring^[1]. The Tudan et al. method was validated against these criteria, which include selectivity (the method measures only what it is supposed to), sensitivity (the lower limit of quantitation is reliably detectable), accuracy and precision over multiple runs, and stability under the conditions the samples will experience.

Validation is the difference between a method that works once under ideal conditions and a method that a different laboratory can run on a Monday morning and trust. For clinical pharmacokinetics, that reproducibility determines whether two studies conducted at different sites can be compared at all.

Three practical uses for this kind of assay

First, pharmacokinetic research. Semaglutide has a long half-life (approximately one week) and is dosed once weekly. Understanding how concentration evolves over a dosing interval, how it varies across patients, and how factors such as body weight, renal function, or co-medications affect exposure requires a reliable plasma assay. Studies that generated the approved dosing regimens for Ozempic and Wegovy depended on exactly this type of bioanalytical infrastructure^[1].

Second, compounded product quality testing. Since the FDA declared the national semaglutide shortage resolved in 2025 and signalled the wind-down of compounding exemptions, the central question for anyone who obtained compounded semaglutide has been whether they received the stated dose of the stated compound. A validated HPLC-MS/MS method is one of the few ways to answer that question definitively. The method reported here is designed for human plasma, not for finished-product testing of injection solutions, but the same analytical principles underlie both applications.

Third, authenticity testing and grey-market surveillance. Regulatory bodies and independent researchers have documented wide variation in the actual peptide content of products sold as semaglutide through unregulated channels. Without a validated reference method, no independent potency check is possible. The authors note that the method may extend to other GLP-1 peptide-based therapeutics with similar structural and physicochemical properties^[1], which suggests its potential scope beyond semaglutide alone.

The measurement gap this fills

The paper frames its contribution explicitly as filling a gap in analytical methodology for semaglutide in human plasma^[1]. Earlier work on semaglutide quantitation in biological matrices relied on immunoassay platforms (ligand-binding assays), which are faster and cheaper but less specific. Mass spectrometry assays can distinguish between the intact drug and metabolites or degradants that share immunological cross-reactivity with the parent compound. That distinction matters in pharmacokinetic studies where the active compound concentration, not total immunoreactive material, is the relevant variable.

A 2026 study in BMC Chemistry validated a parallel HPLC method for semaglutide and tirzepatide in pharmaceutical dosage forms and rat plasma, covering stability under stress conditions including acid/base hydrolysis, oxidation, and light exposure^[2]. The two papers together illustrate a broader trend: as the GLP-1 drug class grows, the analytical infrastructure to characterise, monitor, and verify these compounds is being built out alongside it.

What this does not mean

A validated plasma assay is a research and quality-control tool, not a consumer product. Plasma semaglutide measurement requires clinical-grade sample collection, handling, and laboratory infrastructure. The existence of validated methods does not make routine therapeutic drug monitoring of semaglutide a standard clinical practice; it is primarily used in clinical trials and pharmacokinetic studies.

For patients and researchers following the semaglutide evidence base, the practical implication is this: the pharmacokinetic data underpinning approved dosing, the safety monitoring in ongoing trials, and the independent quality checks on semaglutide products all depend on methods like this one. Better methods mean more reliable data, and more reliable data means better-founded conclusions about how the drug behaves in real patients.